title: Effect of lappaconitine on neuropathic pain mediated by P2X3 receptor in rat dorsal root ganglion.
abstract: ATP facilitates initiation and transmission of the neuropathic pain at the dorsal root ganglion (DRG) level via the P2X receptors, especially the subtype P2X(3). Lappaconitine (LA) is an active principle isolated from Chinese herbal medicine and possesses analgesic effect. The aim of this study was to investigate the effect of LA on chronic constriction injury (CCI)-induced neuropathic pain mediated by P2X(3) receptor in the DRG neurons. In the presence of CCI and/or LA, the mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were measured and P2X(3) receptor expression in the DRG neurons was evaluated by immunohistochemistry and Western blotting. Following intrathecal administration of P2X(3) receptor oligonucleotide, the effect of LA on pain thresholds was assessed. Furthermore, the effect of LA on the P2X(3) receptor agonists ATP- and α,β-meATP-induced inward currents (I(ATP) and I(α,β-meATP)) in the acutely dissociated rat DRG neurons was investigated by whole cell patch-clamp. The results included: (1) There showed reduction of pain thresholds, enhancement of I(ATP) and I(α,β-meATP) and up-regulation of P2X(3) receptor expression in rat DRG neurons when neuropathic pain occurred. (2) In the presence of LA, the decreased pain thresholds, the up-regulated P2X(3) receptor expression and the enhanced I(ATP) and I(α,β-meATP) were reversible in the CCI rats. (3) The down-regulated P2X(3) receptor expression with pretreatment of P2X(3) receptor antisense oligonucleotide significantly attenuated the analgesic effect of LA. These results indicate that the analgesic effect of LA involves decrease of expression and sensitization of the P2X(3) receptors of the rat DRG neurons following CCI.
authors.affiliation: Department of Neurobiology, Chongqing Key Laboratory of Neurobiology, College of Basic Medical Sciences, Third Military Medical University, Chongqing 400038, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Ou
authors.forename: Yan-Dong
authors.initials: YD
authors.lastname: Zhao
authors.forename: Zhi
authors.initials: Z
authors.lastname: Xiao
authors.forename: Hui-Zhong
authors.initials: HZ
authors.lastname: Wen
authors.forename: Jian
authors.initials: J
authors.lastname: Cui
authors.forename: Huai-Zhen
authors.initials: HZ
authors.lastname: Ruan
mesh_terms: D000157:Aconitine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D005727:Ganglia, Spinal / Q000187:drug effects / Q000502:physiology*; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D058477:Receptors, Purinergic P2X3 / Q000502:physiology*
chemical_list: D058477:Receptors, Purinergic P2X3; D000157:Aconitine; C022150:lappaconitine